BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
“We are pleased to welcome Giancarlo to BeiGene in what continues to be a transformative journey for us, solidifying our position as a top global oncology innovator. Giancarlo brings a wealth of experience and a proven track record in the pharmaceutical industry, which will be instrumental as we continue to grow our presence in
Mr. Benelli is a global executive with over 20 years of experience in the pharmaceutical industry including at Novartis and AstraZeneca. He was most recently Vice President and Head Radioligand Therapy International Markets at Novartis.
"I am honoured and excited to join BeiGene at such a pivotal point in the Company’s growth,” said Mr. Benelli. "BeiGene's dedication to discovering and developing innovative treatments that are both affordable and accessible resonates deeply with my own personal and professional values. I am eager to connect with more than 800 of our colleagues across
Prior to his role as Head Radioligand Therapy International Markets at Novartis, Mr. Benelli served as General Manager at Advanced Accelerators Applications, where his responsibilities included restructuring the manufacturing, R&D, and commercial organisations in Saint Genis Poully post-Adacap acquisition by Novartis, ensuring business continuity and successfully launching Lutathera in both
Mr. Benelli received a Medical Doctorate degree and a Post Graduate Diploma in Thoracic Surgery, both from University of
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the expected contributions of Mr. Benelli and their impact on BeiGene, BeiGene’s ability to grow its presence in
To access BeiGene media resources, please visit our News & Media site.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250105648693/en/
Media Contact:
Maryline Iva
+41 61 685 2090
media@beigene.com
Investor Contact:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Source: BeiGene, Ltd.